Cargando…

Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed

INTRODUCTION: Several new active substances (ASs) targeting neuroblastoma (NBL) are under study. We aim to describe the developmental and regulatory status of a sample of ASs targeting NBL to underline the existing regulatory gaps in product development and to discuss possible improvements. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceci, Adriana, Conte, Rosa, Didio, Antonella, Landi, Annalisa, Ruggieri, Lucia, Giannuzzi, Viviana, Bonifazi, Fedele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377668/ https://www.ncbi.nlm.nih.gov/pubmed/37521350 http://dx.doi.org/10.3389/fmed.2023.1113460

Ejemplares similares

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
por: Giannuzzi, Viviana, et al.
Publicado: (2017)

Paediatric Medicines in Europe: The Paediatric Regulation—Is It Time for Reform?
por: Toma, Maddalena, et al.
Publicado: (2021)

Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs
por: Giannuzzi, Viviana, et al.
Publicado: (2017)

PedCRIN tool for the biosamples management in pediatric clinical trials
por: Giannuzzi, Viviana, et al.
Publicado: (2023)

Editorial: Reviews in: regulatory science
por: Kerpel-Fronius, Sandor, et al.
Publicado: (2023)

Ethical and procedural issues for applying researcher-driven multi-national paediatric clinical trials in and outside the European Union: the challenging experience of the DEEP project
por: Giannuzzi, Viviana, et al.
Publicado: (2021)

Paediatric clinical research in Europe: an insight on experts’ needs and perspectives
por: Ruggieri, Lucia, et al.
Publicado: (2021)

Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework
por: Carvalho, Marta, et al.
Publicado: (2017)

A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations
por: Salazar-Fontana, Laura I.
Publicado: (2022)

Classification system for nanotechnology-enabled health products with both scientific and regulatory application
por: Rodríguez-Gómez, Francisco D., et al.
Publicado: (2023)

The ethical framework for performing research with rare inherited neurometabolic disease patients
por: Giannuzzi, Viviana, et al.
Publicado: (2017)

Editorial: The use of real world data for regulatory purposes in the rare diseases setting
por: Giannuzzi, Viviana, et al.
Publicado: (2022)

PB2515: A PILOT STUDY OF THE INTERNATIONAL HEMOGLOBINOPATHY RESEARCH NETWORK (INHERENT)
por: Kountouris, Petros, et al.
Publicado: (2023)

Tools Are Needed to Promote Sedation Practices for Mechanically Ventilated Patients
por: Wang, Tao, et al.
Publicado: (2021)

Successful private–public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines
por: Ruggieri, L., et al.
Publicado: (2014)

Feature Genes in Neuroblastoma Distinguishing High-Risk and Non-high-Risk Neuroblastoma Patients: Development and Validation Combining Random Forest With Artificial Neural Network
por: Yang, Sha, et al.
Publicado: (2022)

The Use of Remote Monitoring Technologies: A Review of Recent Regulatory Scientific Advices, Qualification Opinions, and Qualification Advices Issued by the European Medicines Agency
por: Dekker, Marieke J. H. J., et al.
Publicado: (2021)

Occurrence of Albifimbria verrucaria in the Blood of a Female Child With Neuroblastoma
por: Masetti, Riccardo, et al.
Publicado: (2020)

Is neuroblastoma screening evaluation needed and feasible?
por: Estève, J., et al.
Publicado: (1995)

MIBG Therapy for Neuroblastoma: Precision Achieved With Dosimetry, and Concern for False Responders
por: Rubio, Pedro M., et al.
Publicado: (2020)

Patient-derived models: Advanced tools for precision medicine in neuroblastoma
por: Aaltonen, Kristina, et al.
Publicado: (2023)

Validation of the ICEBERG emergency room screening tool for early identification of older patients with geriatric consultation needs
por: Bischoff-Ferrari, Heike A., et al.
Publicado: (2023)

Imaging neuroblastoma: what the radiologist needs to know
por: McCarville, M.B.
Publicado: (2011)

The impact on the scientific community of the 2018 addendum to the CHCC
por: Caproni, Marzia, et al.
Publicado: (2022)

Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma
por: Florea, Ana-Maria, et al.
Publicado: (2017)

Online Information on Probiotics: Does It Match Scientific Evidence?
por: Neunez, Marie, et al.
Publicado: (2020)

Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative
por: Brito, Maria de Fátima, et al.
Publicado: (2021)

Nutraceutical Preventative and Therapeutic Potential in Neuroblastoma: From Pregnancy to Early Childhood
por: Sbaffone, Maddalena, et al.
Publicado: (2022)

Immunosuppressive Microenvironment in Neuroblastoma
por: Pistoia, Vito, et al.
Publicado: (2013)

Introducing the MAVEN Leadership Training Initiative to diversify the scientific workforce
por: Wang, Y Claire, et al.
Publicado: (2021)

Evaluation of the impact of reliance on the regulatory performance in the South African Health Products Regulatory Authority: implications for African regulatory authorities
por: Danks, Lorraine, et al.
Publicado: (2023)

Unusual Reactions to Hymenoptera Stings: Current Knowledge and Unmet Needs in the Pediatric Population
por: Castagnoli, Riccardo, et al.
Publicado: (2021)

The Role of Transthoracic Ultrasound in the novel Coronavirus Disease (COVID-19): A Reappraisal. Information and Disinformation: Is There Still Place for a Scientific Debate?
por: Quarato, Carla Maria Irene, et al.
Publicado: (2020)

Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan
por: Maeda, Hideki, et al.
Publicado: (2022)

Reply from authors: The scientific method is needed to create scientific principles
por: D'Onofrio, Augusto, et al.
Publicado: (2022)

Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy
por: Hines, Philip A., et al.
Publicado: (2020)

Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells
por: Cappabianca, Lucia, et al.
Publicado: (2022)

5613464 INTEGRATION OF PHARMACOKINETIC AND PHARMACODYNAMIC MODELS TO MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR PROSPECTIVE ASSESSMENT OF THE RISK-BENEFIT RATIO OF ORAL IRON CHELATORS IN PAEDIATRIC PATIENTS WITH TRANSFUSION-DEPENDENT HAEMOGLOBINOPATHIES
por: Della Pasqua, O.D.P., et al.
Publicado: (2023)

Future directions in regulatory affairs
por: Chisholm, Orin, et al.
Publicado: (2023)

Translational Medicine in the Era of Social Media: A Survey of Scientific and Clinical Communities
por: Sandalova, Elena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gs4fba6tlj26oc35019fnpvssh